Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 2.94% is 97% below its 5-year average of 111.55%, near the low end of its 5-year range (2.94%–224.68%).
As of the fiscal period ended Wednesday, December 31, 2025. 90.20% below its 12-month average of 29.98%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
2.94%
RETURN ON EQUITY (ROE) AVG TTM
29.98%
RETURN ON EQUITY (ROE) AVG 3Y
64.02%
RETURN ON EQUITY (ROE) AVG 5Y
111.55%
RETURN ON EQUITY (ROE) AVG 10Y
43.61%
RETURN ON EQUITY (ROE) AVG 15Y
29.23%
RETURN ON EQUITY (ROE) AVG 20Y
36.23%
CURRENT VS TTM AVG
-90.20%
CURRENT VS 3Y AVG
-95.41%
CURRENT VS 5Y AVG
-97.36%
CURRENT VS 10Y AVG
-93.26%
CURRENT VS 15Y AVG
-89.94%
CURRENT VS 20Y AVG
-91.89%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-73.00%
vs the sector median at left
Waters Corporation
Market Cap
$24.59B
Return on Equity (ROE)
2.94%
TTM Avg
29.98%
3Y Avg
64.02%
5Y Avg
111.55%
Market Cap
$24.23B
Return on Equity (ROE)
25.41%
TTM Avg
12.92%
3Y Avg
11.29%
5Y Avg
9.83%
Market Cap
$24.00B
Return on Equity (ROE)
18.89%
TTM Avg
16.95%
3Y Avg
19.08%
5Y Avg
20.56%
Market Cap
$25.35B
Return on Equity (ROE)
11.65%
TTM Avg
9.71%
3Y Avg
9.35%
5Y Avg
12.84%
Market Cap
$25.72B
Return on Equity (ROE)
14.13%
TTM Avg
13.34%
3Y Avg
14.07%
5Y Avg
18.07%
Market Cap
$22.91B
Return on Equity (ROE)
-6.79%
TTM Avg
-4.55%
3Y Avg
10.63%
5Y Avg
21.70%
Market Cap
$21.98B
Return on Equity (ROE)
21.82%
TTM Avg
18.68%
3Y Avg
17.25%
5Y Avg
16.03%
Market Cap
$21.75B
Return on Equity (ROE)
-46.61%
TTM Avg
-32.64%
3Y Avg
-13.90%
5Y Avg
0.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Waters Corporation (WAT) | $24.59B | 2.94% | 29.98% | 64.02% | 111.55% |
| Incyte Corporation (INCY)vs › | $24.23B | 25.41% | 12.92% | 11.29% | 9.83% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.00B | 18.89% | 16.95% | 19.08% | 20.56% |
| Labcorp Holdings Inc. (LH)vs › | $25.35B | 11.65% | 9.71% | 9.35% | 12.84% |
| Quest Diagnostics Incorporated (DGX)vs › | $25.72B | 14.13% | 13.34% | 14.07% | 18.07% |
| BioNTech SE (BNTX)vs › | $22.91B | -6.79% | -4.55% | 10.63% | 21.70% |
| STERIS plc (STE)vs › | $22.26B | 10.89% | 10.12% | 7.00% | 7.00% |
| United Therapeutics Corporation (UTHR)vs › | $21.98B | 21.82% | 18.68% | 17.25% | 16.03% |
| Moderna, Inc. (MRNA)vs › | $21.75B | -46.61% | -32.64% | -13.90% | 0.25% |
| Alnylam Pharmaceuticals, Inc. (ALNY)vs › | $27.44B | 59.67% | -187.43% | 134.89% | 51.69% |
ROE
2.9%
ROA
1.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 25.09% |
| 2024-12-31 | 34.88% |
| 2023-12-31 | 55.83% |
| 2022-12-31 | 140.29% |
| 2021-12-31 | 188.50% |
| 2020-12-31 | 224.68% |
| 2019-12-31 | -273.81% |
| 2018-12-31 | 37.89% |
| 2017-12-31 | 0.91% |
| 2016-12-31 | 22.65% |
| 2015-12-31 | 22.78% |
| 2014-12-31 | 22.78% |
| 2013-12-31 | 25.52% |
| 2012-12-31 | 31.45% |
| 2011-12-31 | 35.30% |
| 2010-12-31 | 35.72% |
| 2009-12-31 | 38.08% |
| 2008-12-31 | 48.79% |
| 2007-12-31 | 45.74% |
| 2006-12-31 | 61.32% |
| 2005-12-31 | 71.21% |
| 2004-12-31 | 33.01% |
| 2003-12-31 | 28.94% |
| 2002-12-31 | 22.20% |
| 2001-12-31 | 19.69% |
| 2000-12-31 | 32.17% |
| 1999-12-31 | 41.85% |
| 1998-12-31 | 46.73% |
| 1997-12-31 | -11.79% |
| 1996-12-31 | -3.69% |
